Veracyte (VCYT) Liabilities and Shareholders Equity (2016 - 2026)
Veracyte's Liabilities and Shareholders Equity history spans 14 years, with the latest figure at $1.4 billion for Q4 2025.
- On a quarterly basis, Liabilities and Shareholders Equity rose 8.15% to $1.4 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $5.4 billion, a 8.46% increase, with the full-year FY2025 number at $1.4 billion, up 8.15% from a year prior.
- Liabilities and Shareholders Equity hit $1.4 billion in Q4 2025 for Veracyte, up from $1.4 billion in the prior quarter.
- Over the last five years, Liabilities and Shareholders Equity for VCYT hit a ceiling of $1.4 billion in Q4 2025 and a floor of $1.0 billion in Q1 2021.
- Historically, Liabilities and Shareholders Equity has averaged $1.2 billion across 5 years, with a median of $1.2 billion in 2021.
- Biggest five-year swings in Liabilities and Shareholders Equity: soared 300.19% in 2021 and later decreased 5.09% in 2022.
- Tracing VCYT's Liabilities and Shareholders Equity over 5 years: stood at $1.2 billion in 2021, then dropped by 2.64% to $1.2 billion in 2022, then dropped by 3.59% to $1.1 billion in 2023, then increased by 16.6% to $1.3 billion in 2024, then grew by 8.15% to $1.4 billion in 2025.
- Business Quant data shows Liabilities and Shareholders Equity for VCYT at $1.4 billion in Q4 2025, $1.4 billion in Q3 2025, and $1.3 billion in Q2 2025.